IGH-CCND1 Fusion is an inclusion criterion in 28 clinical trials for mantle cell lymphoma, of which 24 are open and 4 are closed. Of the trials that contain IGH-CCND1 Fusion and mantle cell lymphoma as inclusion criteria, 8 are phase 1 (5 open), 6 are phase 1/phase 2 (6 open), 12 are phase 2 (11 open), and 2 are phase 3 (2 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 9 clinical trials for multiple myeloma, of which 6 are open and 3 are closed. Of the trials that contain IGH-CCND1 Fusion and multiple myeloma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (2 open), 3 are phase 2 (2 open), and 2 are phase 3 (2 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 5 clinical trials for follicular lymphoma, of which 3 are open and 2 are closed. Of the trials that contain IGH-CCND1 Fusion and follicular lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 5 clinical trials for diffuse large B-cell lymphoma, of which 3 are open and 2 are closed. Of the trials that contain IGH-CCND1 Fusion and diffuse large B-cell lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 4 clinical trials for chronic lymphocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain IGH-CCND1 Fusion and chronic lymphocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 3 clinical trials for marginal zone lymphoma, of which 2 are open and 1 is closed. Of the trials that contain IGH-CCND1 Fusion and marginal zone lymphoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 3 clinical trials for small lymphocytic lymphoma, of which 2 are open and 1 is closed. Of the trials that contain IGH-CCND1 Fusion and small lymphocytic lymphoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 2 clinical trials for B-cell non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH-CCND1 Fusion and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 2 clinical trials for grade 3b follicular lymphoma, of which 1 is open and 1 is closed. Of the trials that contain IGH-CCND1 Fusion and grade 3b follicular lymphoma as inclusion criteria, 2 are phase 1 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 2 clinical trials for lymphoplasmacytic lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH-CCND1 Fusion and lymphoplasmacytic lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 2 clinical trials for transformed non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain IGH-CCND1 Fusion and transformed non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for EBV-positive diffuse large B-cell lymphoma, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and EBV-positive diffuse large B-cell lymphoma, not otherwise specified as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and high grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for mediastinal large B-cell lymphoma, of which 0 are open and 1 is closed. Of the trial that contains IGH-CCND1 Fusion and mediastinal large B-cell lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for plasma cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and plasma cell leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for primary central nervous system lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and primary central nervous system lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for primary mediastinal B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and primary mediastinal B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for T-cell/histiocyte-rich large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and T-cell/histiocyte-rich large B-cell lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

IGH-CCND1 Fusion is an inclusion criterion in 1 clinical trial for waldenstrom macroglobulinemia, of which 1 is open and 0 are closed. Of the trial that contains IGH-CCND1 Fusion and waldenstrom macroglobulinemia as inclusion criteria, 1 is phase 1 (1 open) [5].